Immunocore Holdings Plc Sponsored ADR IMCR 深 滬
等待開盤 09-06 09:30:00 美东时间
35.98
+0.720
+2.04%
華盛通- 最 高36.205
- 今 開35.33
- 成交量 26.63万股
- 最 低 35.33
- 昨 收 35.26
- 總市值 18.13亿
- 52周最高 39.3295
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 23.15
- 委 比 34.43%
- 總股本 5038.71万
- 歷史最高 76.98
- 量 比 1.78
- 振 幅 2.48%
- 歷史最低 18.43
- 每 手 1
- 風險率 13.91%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Immunocore to present at upcoming investor conferences
Immunocore Holdings plc (Nasdaq: IMCR) announced that its management will participate in several upcoming investor conferences in September 2025, including the Cantor Global Healthcare Conference, H.C. Wainwright 27th Annual Global Investment Conference, Baird 2025 Global Healthcare Conference, and Morgan Stanley 23rd Annual Global Healthcare Conference. Presentations will be available via webcast and replay on Immunocore's website. The company s...
09-04 11:00
Immuron partners with InvestorHub
Immunot Limited has partnered with InvestorHub to launch an interactive investor hub, enhancing communication with shareholders and investors. The platform will feature regular updates, including videos, educational materials, and research. CEO Steven Lydeamore highlighted upcoming milestones: FDA submission and approval of IMM-529 IND and clinical trial results for Travelan®. The company focuses on developing orally administered antibodies for i...
08-27 02:29
Earnings Scheduled For August 7, 2025
Companies Reporting Before The Bell • GoHealth (NASDAQ:GOCO) is estimated to re...
08-07 16:33
Immunocore reports second quarter financial results and provides a business update
Immunocore Holdings plc reported Q2 2025 net revenues of $98.0 million for KIMMTRAK, a 30% year-over-year increase. The company is advancing multiple clinical trials, including TEBE-AM (expected to complete enrollment in 1H 2026) and PRISM-MEL-301 (dose selection expected in 2H 2025). They also presented IMC-I109V HBV data at the 2025 AASLD Liver Meeting. Cash, cash equivalents, and marketable securities totaled $883 million as of June 30, 2025. ...
08-07 11:00
Immunocore to report second quarter 2025 financial results and host call on August 7, 2025
Immunocore Holdings plc (Nasdaq: IMCR), a biotech company specializing in immunomodulating medicines for cancer, infectious, and autoimmune diseases, announced it will release its Q2 financial results before US markets open on August 7, 2025. A live teleconference and webcast to discuss the results will follow at 8:00 a.m. EDT (1:00 p.m. BST). Immunocore’s ImmTAX platform focuses on TCR bispecific immunotherapies, with KIMMTRAK approved for treat...
07-31 06:00
Immutep Announces Positive Update from Phase I Study of IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases
Immutep Limited announces positive initial data from its Phase I study of IMP761, a novel LAG-3 agonist antibody for autoimmune diseases. Results show significant T cell suppression and a favorable safety profile at the 0.9 mg/kg dose level. IMP761 has the potential to silence dysregulated T cells, offering a targeted approach with fewer side effects. The study will continue with higher single ascending doses of 2.5, 7, and 14 mg/kg, with additio...
06-23 12:00
美股大行评级 | 再生元制药遭大摩下调评级，Aspen Insurance Hldgs(AHL)获多家机构首予“超配”评级！
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1136585934532136961.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• HC Wainwright & Co.：维持Vera Therapeutics(VERA)"买入"评级，目标价从75美元升至85美元</p> <p>• Ascendiant Capital：维持60 Degrees
06-03 09:06
Demystifying Immunocore Holdings: Insights From 9 Analyst Reviews
During the last three months, 9 analysts shared their evaluations of Immunocore...
06-03 05:00
Immunocore to present at the 2025 Jefferies Global Healthcare Conference
Immunocore's management will participate in the 2025 Jefferies Global Healthcare Conference on June 5, 2025, at 11:05 a.m. EDT. The event will be available via webcast on Immunocore's investor webpage and replayed for limited time. Immunocore is a biotech company developing innovative TCR bispecific immunotherapies for cancer, autoimmune diseases, and infectious diseases. Their lead oncology product, KIMMTRAK, has been approved in multiple region...
06-02 11:00
Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma
Results from the Phase 1b trial of IMA203 PRAME cell therapy in 33 heavily pretreated metastatic melanoma patients show favorable tolerability and durable clinical activity, with a confirmed ORR of 56%, mDOR of 12.1 months, mPFS of 6.1 months, and mOS of 15.9 months. Subgroup analyses demonstrate strong responses in both cutaneous (cORR 50%) and uveal melanoma (cORR 67%). These findings support the ongoing SUPRAME Phase 3 trial and highlight Imma...
05-31 12:00
